Passage Bio is a genetic medicines company developing therapies for the treatment of rare monogenic central nervous system diseases. Passage Bio develops a portfolio of 5 rare disease indications in the neuro/CNS genetic space through IND-enabling studies using AAV technology and know-how.
|HQ||Philadelphia, PA, US||Map|
Net income (Q1, 2021)
EBIT (Q1, 2021)
Market capitalization (12-Nov-2021)
Closing stock price (12-Nov-2021)
Passage Bio has 492 Twitter Followers. The number of followers has increased 6.8% month over month and increased 19.8% quarter over quarter
Tweets last 30 days
Avg. likes per Tweet
Tweets with engagement
When was Passage Bio founded?
Passage Bio was founded in 2018.
Who are Passage Bio key executives?
Passage Bio's key executives are Bruce Goldsmith, Karen Anderson and Andrea Campanile.
How many employees does Passage Bio have?
Passage Bio has 20 employees.
Who are Passage Bio competitors?
Competitors of Passage Bio include Taysha Gene Therapies, Angionetics and DegenRx.
Where is Passage Bio headquarters?
Passage Bio headquarters is located at 2001 Market St, Philadelphia.
Where are Passage Bio offices?
Passage Bio has an office in Philadelphia.
How many offices does Passage Bio have?
Passage Bio has 1 office.
Receive alerts for 300+ data fields across thousands of companies